GlobeNewswire
-
SHARP Surgery Center Opens Four-Room Ambulatory Surgery Center in Austin Built Around the SHARP Method
18/11/2026 -
PRF or PRP Hair Treatment: What Actually Separates the Two Platelet Preparations, and Why Patients Are Rarely Told Which One They Receive
18/11/2026 -
Optimi Health Outlines 2027 Plans for OPTI-101 Phase 2b in Major Depressive Disorder and OPTI-201 Phase 3 in PTSD; Announces Shares-for-Debt Settlement
18/11/2026 -
Immuneering Presents Data That Supports Expanding the Clinical Evaluation of Atebimetinib to Anaplastic Thyroid Cancer
18/11/2026 -
Immuneering Presents Additional Data Demonstrating Atebimetinib’s Broad Potential as a Backbone for Combination Therapy in Pancreatic Cancer
18/11/2026 -
Surgery Partners, Inc. Announces Increased Consent Fee in Consent Solicitation Relating to Surgery Center Holdings, Inc.’s 7.250% Senior Notes due 2032
18/11/2026 -
Zevra Therapeutics to Present at the Piper Sandler Annual Healthcare Conference
18/11/2026 -
CMS Finalizes Reassignment of Gastric Alimetry® Test to Higher Payment Level, Increasing Medicare Hospital Outpatient Payment by Approximately 144%
18/11/2026 -
Allarity Therapeutics Granted U.S. Patent for Stenoparib’s Clinical Dosing Regimen, with Protection Into 2045
18/11/2026 -
Quantum-Si Achieves Historic Milestone in Protein Sequencing with Single-Molecule Detection of All 20 Amino Acids on Proteus™
18/11/2026 -
Enlivex Announces Positive Interim DSMB Safety Review, Supporting Continued Enrollment in Phase IIb Knee Osteoarthritis Trial
18/11/2026 -
Actuate Therapeutics Reports Positive Monotherapy Data in Aggressive Melanoma Preclinical Model with Daily Dosing of Elraglusib Oral Tablet at ENA 2026
18/11/2026 -
Retension Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate Update
18/11/2026 -
Telomir Pharmaceuticals Selects Linical to Advance FDA-Cleared Phase 1/2 Clinical Trial of Telomir-Zn in Triple-Negative Breast Cancer
18/11/2026 -
Scribe Therapeutics Presents New Data Advancing the Potential of Ultra-Long-Acting Genetic Medicines for Cardiovascular Disease at AHA Scientific Sessions 2026
18/11/2026 -
Iambic Presents Preclinical Data for CDK2/4 Inhibitor IAM-C1 and Brain-Penetrant KIF18A Inhibitor IAM217 at 2026 EORTC-NCI-AACR Symposium
18/11/2026 -
Major Memphis Health System Expands BVA® Adoption to New Hospital Outpatient Site
18/11/2026 -
Aradigm Selects City of Hope as a Preferred National Destination for Cell and Gene Therapy
18/11/2026 -
BillionToOne to Participate in the Piper Sandler 38th Annual Healthcare Conference
18/11/2026
Pages